Desjardins Global Asset Management Inc. Sells 146 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Desjardins Global Asset Management Inc. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,165 shares of the biotechnology company’s stock after selling 146 shares during the period. Desjardins Global Asset Management Inc.’s holdings in United Therapeutics were worth $1,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of United Therapeutics by 5.4% in the first quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock valued at $1,064,249,000 after purchasing an additional 241,594 shares in the last quarter. Vanguard Group Inc. boosted its stake in United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after buying an additional 20,373 shares during the period. State Street Corp boosted its stake in United Therapeutics by 4.5% during the second quarter. State Street Corp now owns 1,875,758 shares of the biotechnology company’s stock worth $414,074,000 after buying an additional 80,656 shares during the period. Wellington Management Group LLP boosted its stake in United Therapeutics by 73.7% during the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after buying an additional 710,668 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of United Therapeutics by 14.9% during the first quarter. Geode Capital Management LLC now owns 759,143 shares of the biotechnology company’s stock worth $169,811,000 after purchasing an additional 98,267 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher Patusky sold 1,680 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the completion of the transaction, the director now owns 4 shares in the company, valued at approximately $896. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 128,590 shares of company stock valued at $30,149,097. 12.50% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

UTHR stock opened at $231.78 on Wednesday. The firm has a market cap of $10.91 billion, a price-to-earnings ratio of 11.68 and a beta of 0.52. The firm has a 50-day simple moving average of $230.21 and a two-hundred day simple moving average of $228.33. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s quarterly revenue was up 25.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.67 earnings per share. On average, equities analysts forecast that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UTHR. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Wedbush reiterated an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. SVB Leerink began coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.67.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.